

Pulsed Field Ablation Market Size, Share & Trends Analysis Report By Components (Catheters, Generators), By Indication (Atrial Fibrillation, Non Atrial Fibrillation), By End Use (Inpatient, Outpatient), By Region, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/P9272B88654FEN.html>

Date: December 2024

Pages: 100

Price: US\$ 5,950.00 (Single User License)

ID: P9272B88654FEN

Abstracts

This report can be delivered to the clients within 2 Business Days

Pulsed Field Ablation Market Size & Trends

The global pulsed field ablation market size was estimated at USD 913.1 million in 2024 and is projected to grow at a CAGR of 33.1% from 2025 to 2030. This is driven by its promise as a safer and more effective alternative to traditional thermal ablation methods. As the global prevalence of atrial fibrillation (AF) rises, there is an increasing demand for innovative treatment options that offer fewer complications and improved outcomes. Pulsed field ablation (PFA) non-thermal mechanism significantly reduces the risk of damaging surrounding tissues, a major limitation of conventional ablation techniques like radiofrequency and cryoablation. This unique advantage has led to growing interest from healthcare providers and patients, accelerating its adoption in clinical settings.

Cardiac arrhythmias, particularly atrial fibrillation (AF), are increasingly prevalent, affecting millions worldwide. AF, characterized by an irregular and often rapid heart rate, is the most common type of sustained arrhythmia, significantly raising the risk of stroke, heart failure, and other serious cardiovascular complications. As global populations age and the incidence of lifestyle-related risk factors, such as hypertension and obesity, rises, the number of AF cases continues to grow. According to the Johnson & Johnson Services, Inc. article published in February 2024, more than 37.5 million people globally live with this condition, emphasizing its widespread impact. The risk of developing AFib

is notably high; statistics reveal that about one in four adults over the age of 40 experience this arrhythmia at some point in their lives. This growing prevalence highlights the urgent need for effective management and prevention strategies.

This escalating burden has created a substantial demand for effective, minimally invasive treatment options. Traditional therapies such as antiarrhythmic drugs and catheter-based ablation have limitations, leading to an unmet need for safer, more efficient approaches. The increasing prevalence of arrhythmias is thus a key driver of market growth for advanced treatment technologies like pulsed field ablation (PFA), which offer improved safety profiles and efficacy compared to conventional methods. In February 2024, an article in *The Lancet Regional Health - Europe* highlighted that atrial fibrillation (AF) affects 1.5-2% of European adults, expected to rise to 9.5% in those over 65 by 2060. AF is a significant risk factor for stroke, dementia, heart failure, and premature mortality, posing challenges for the aging population and healthcare systems.

Technological advancements are a key driver of the PFA industry's growth, as ongoing innovations enhance ablation procedures' precision, safety, and efficacy. Leading medical device companies are investing heavily in the development of next-generation PFA systems, focusing on improving energy delivery, catheter design, and procedural efficiency. Innovations in catheter flexibility and the integration of real-time imaging and mapping technologies allow for more targeted and controlled ablation, reducing the risk of complications and improving patient outcomes. In October 2024, Abbott announced important advancements in its pulsed field ablation technologies for electrophysiology. The company finished enrolling participants in the VOLT-AF IDE Study aimed at evaluating the Volt PFA System and initiated the FOCALFLEX trial to test the TactiFlex DuAblation Catheter for treating paroxysmal atrial fibrillation. These initiatives mark significant progress for Abbott's PFA catheters.

Regulatory approvals are critical in influencing the PFA industry, as they validate the safety and efficacy of these novel devices, paving the way for broader clinical adoption. In recent years, several PFA systems have received CE marking in Europe, allowing them to be marketed and used across the continent. These approvals are often based on positive clinical trial results that demonstrate the benefits of PFA over traditional methods, particularly in terms of reduced procedure times and fewer complications. In October 2024, Medtronic received FDA approval for the Affera Mapping and Ablation System with Sphere-9 Catheter, designed for persistent atrial fibrillation and atrial flutter treatment. This makes Medtronic the first company with two FDA-approved pulsed-field ablation (PFA) technologies for AFib. The Sphere-9 catheter offers flexible treatment options with its 9mm lattice tip, complementing the PulseSelect PFA System, which

provides a single-shot solution for pulmonary vein isolation.

Global Pulsed Field Ablation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global pulsed field ablation market report based on the components, indication, end use, and region.

Components Outlook (Revenue, USD Million, 2018 - 2030)

Catheters

Generators

Indication Outlook (Revenue, USD Million, 2018 - 2030)

Atrial Fibrillation

Non-atrial Fibrillation

End-use Outlook (Revenue, USD Million, 2018 - 2030)

Inpatient Facilities

Outpatient Facilities

Regional Outlook (Revenue, USD Million; 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Norway

Denmark

Sweden

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
 - 1.2.1. Components
 - 1.2.2. Indication
 - 1.2.3. End use
 - 1.2.4. Regional Scope
 - 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased database
 - 1.4.2. GVR's internal database
 - 1.4.3. Secondary sources
 - 1.4.4. Primary research
 - 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
 - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity flow analysis (Model 1)
 - 1.7.2. Approach 1: Commodity flow approach
 - 1.7.3. Volume price analysis (Model 2)
 - 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
 - 2.2.1. Components outlook
 - 2.2.2. Indication outlook
 - 2.2.3. End use outlook
- 2.3. Regional outlook
- 2.4. Competitive Insights

CHAPTER 3. PULSED FIELD ABLATION MARKET VARIABLES, TRENDS & SCOPE

3.1. Market Lineage Outlook

3.1.1. Parent Market Outlook

3.1.2. Related/ancillary market outlook

3.2. Market Dynamics

3.2.1. Market Driver Analysis

3.2.1.1. Rising prevalence of cardiac arrhythmias

3.2.1.2. Technological advancements in PFA devices

3.2.1.3. Minimally invasive nature of PFA

3.2.2. Market Restraint Analysis

3.2.2.1. High costs of PFA devices and procedures

3.2.2.2. Lack of long-term data on effectiveness and safety

3.3. Pulsed Field Ablation Market Analysis Tools

3.3.1. Industry Analysis – Porter's

3.3.1.1. Bargaining power of suppliers

3.3.1.2. Bargaining power of buyers

3.3.1.3. Threat of substitutes

3.3.1.4. Threat of new entrants

3.3.1.5. Competitive rivalry

3.3.2. PESTEL Analysis

3.3.2.1. Political landscape

3.3.2.2. Economic landscape

3.3.2.3. Social landscape

3.3.2.4. Technological landscape

3.3.2.5. Environmental landscape

3.3.2.6. Legal landscape

CHAPTER 4. PULSED FIELD ABLATION MARKET: COMPONENTS ESTIMATES & TREND ANALYSIS

4.1. Segment Dashboard

4.2. Pulsed Field Ablation Market: Components Movement Analysis

4.3. Pulsed Field Ablation Market by Components Outlook (USD Million)

4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following

4.5. Catheters

4.5.1. Catheters Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

4.6. Generators

4.6.1. Generators Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 5. PULSED FIELD ABLATION MARKET: INDICATION ESTIMATES & TREND ANALYSIS

5.1. Segment Dashboard

5.2. Pulsed Field Ablation Market: Indication Movement Analysis

5.3. Pulsed Field Ablation Market by Indication Outlook (USD Million)

5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following

5.5. Atrial Fibrillation

5.5.1. Atrial Fibrillation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

5.6. Non-Atrial Fibrillation

5.6.1. Non-Atrial Fibrillation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 6. PULSED FIELD ABLATION MARKET: END USE ESTIMATES & TREND ANALYSIS

6.1. Segment Dashboard

6.2. Pulsed Field Ablation Market: End Use Movement Analysis

6.3. Pulsed Field Ablation Market by End Use Outlook (USD Million)

6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following

6.5. Inpatient Facilities

6.5.1. Inpatient Facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6. Outpatient Facilities

6.6.1. Outpatient Facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 7. PULSED FIELD ABLATION MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

7.1. Regional Dashboard

7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030

7.3. North America

7.3.1. U.S.

7.3.1.1. Key country dynamics

- 7.3.1.2. Regulatory framework/ reimbursement structure
- 7.3.1.3. Competitive scenario
- 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.2. Canada
 - 7.3.2.1. Key country dynamics
 - 7.3.2.2. Regulatory framework/ reimbursement structure
 - 7.3.2.3. Competitive scenario
 - 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.3. Mexico
 - 7.3.3.1. Key country dynamics
 - 7.3.3.2. Regulatory framework/ reimbursement structure
 - 7.3.3.3. Competitive scenario
 - 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4. Europe
 - 7.4.1. UK
 - 7.4.1.1. Key country dynamics
 - 7.4.1.2. Regulatory framework/ reimbursement structure
 - 7.4.1.3. Competitive scenario
 - 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.4.2. Germany
 - 7.4.2.1. Key country dynamics
 - 7.4.2.2. Regulatory framework/ reimbursement structure
 - 7.4.2.3. Competitive scenario
 - 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.4.3. France
 - 7.4.3.1. Key country dynamics
 - 7.4.3.2. Regulatory framework/ reimbursement structure
 - 7.4.3.3. Competitive scenario
 - 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.4.4. Italy
 - 7.4.4.1. Key country dynamics
 - 7.4.4.2. Regulatory framework/ reimbursement structure
 - 7.4.4.3. Competitive scenario
 - 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.4.5. Spain
 - 7.4.5.1. Key country dynamics
 - 7.4.5.2. Regulatory framework/ reimbursement structure
 - 7.4.5.3. Competitive scenario
 - 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)

7.4.6. Norway

7.4.6.1. Key country dynamics

7.4.6.2. Regulatory framework/ reimbursement structure

7.4.6.3. Competitive scenario

7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)

7.4.7. Sweden

7.4.7.1. Key country dynamics

7.4.7.2. Regulatory framework/ reimbursement structure

7.4.7.3. Competitive scenario

7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)

7.4.8. Denmark

7.4.8.1. Key country dynamics

7.4.8.2. Regulatory framework/ reimbursement structure

7.4.8.3. Competitive scenario

7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)

7.5. Asia Pacific

7.5.1. Japan

7.5.1.1. Key country dynamics

7.5.1.2. Regulatory framework/ reimbursement structure

7.5.1.3. Competitive scenario

7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)

7.5.2. China

7.5.2.1. Key country dynamics

7.5.2.2. Regulatory framework/ reimbursement structure

7.5.2.3. Competitive scenario

7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)

7.5.3. India

7.5.3.1. Key country dynamics

7.5.3.2. Regulatory framework/ reimbursement structure

7.5.3.3. Competitive scenario

7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)

7.5.4. Australia

7.5.4.1. Key country dynamics

7.5.4.2. Regulatory framework/ reimbursement structure

7.5.4.3. Competitive scenario

7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)

7.5.5. South Korea

7.5.5.1. Key country dynamics

7.5.5.2. Regulatory framework/ reimbursement structure

7.5.5.3. Competitive scenario

7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)

7.5.6. Thailand

7.5.6.1. Key country dynamics

7.5.6.2. Regulatory framework/ reimbursement structure

7.5.6.3. Competitive scenario

7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)

7.6. Latin America

7.6.1. Brazil

7.6.1.1. Key country dynamics

7.6.1.2. Regulatory framework/ reimbursement structure

7.6.1.3. Competitive scenario

7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)

7.6.2. Argentina

7.6.2.1. Key country dynamics

7.6.2.2. Regulatory framework/ reimbursement structure

7.6.2.3. Competitive scenario

7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)

7.7. MEA

7.7.1. South Africa

7.7.1.1. Key country dynamics

7.7.1.2. Regulatory framework/ reimbursement structure

7.7.1.3. Competitive scenario

7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)

7.7.2. Saudi Arabia

7.7.2.1. Key country dynamics

7.7.2.2. Regulatory framework/ reimbursement structure

7.7.2.3. Competitive scenario

7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)

7.7.3. UAE

7.7.3.1. Key country dynamics

7.7.3.2. Regulatory framework/ reimbursement structure

7.7.3.3. Competitive scenario

7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

7.7.4. Kuwait

7.7.4.1. Key country dynamics

7.7.4.2. Regulatory framework/ reimbursement structure

7.7.4.3. Competitive scenario

7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Market Participant Categorization

8.2. Key Company Profiles

8.2.1. Boston Scientific Corporation

8.2.1.1. Company overview

8.2.1.2. Financial performance

8.2.1.3. Product benchmarking

8.2.1.4. Strategic initiatives

8.2.2. Abbott

8.2.2.1. Company overview

8.2.2.2. Financial performance

8.2.2.3. Product benchmarking

8.2.2.4. Strategic initiatives

8.2.3. Medtronic

8.2.3.1. Company overview

8.2.3.2. Financial performance

8.2.3.3. Product benchmarking

8.2.3.4. Strategic initiatives

8.2.4. Biosense Webster, Inc. (Johnson & Johnson Services, Inc)

8.2.4.1. Company overview

8.2.4.2. Financial performance

8.2.4.3. Product benchmarking

8.2.4.4. Strategic initiatives

8.2.5. Pulse Biosciences, Inc

8.2.5.1. Company overview

8.2.5.2. Financial performance

8.2.5.3. Product benchmarking

8.2.5.4. Strategic initiatives

8.2.6. Kardium

8.2.6.1. Company overview

8.2.6.2. Financial performance

8.2.6.3. Product benchmarking

8.2.6.4. Strategic initiatives

8.2.7. Jia Jing Electronic Co., Ltd.

8.2.7.1. Company overview

8.2.7.2. Financial performance

8.2.7.3. Product benchmarking

- 8.2.7.4. Strategic initiatives
- 8.2.8. Adagio Medical Inc
 - 8.2.8.1. Company overview
 - 8.2.8.2. Financial performance
 - 8.2.8.3. Product benchmarking
 - 8.2.8.4. Strategic initiatives
- 8.2.9. CardioFocus
 - 8.2.9.1. Company overview
 - 8.2.9.2. Financial performance
 - 8.2.9.3. Product benchmarking
 - 8.2.9.4. Strategic initiatives
- 8.2.10. Acutus Medical, Inc
 - 8.2.10.1. Company overview
 - 8.2.10.2. Financial performance
 - 8.2.10.3. Product benchmarking
 - 8.2.10.4. Strategic initiatives

I would like to order

Product name: Pulsed Field Ablation Market Size, Share & Trends Analysis Report By Components (Catheters, Generators), By Indication (Atrial Fibrillation, Non Atrial Fibrillation), By End Use (Inpatient, Outpatient), By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/P9272B88654FEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P9272B88654FEN.html>